Scholar Rock Holding Corp

Insider sale by Scholar Rock’s chief scientist shows a slight dip and strategic portfolio shift—an insight into leadership confidence and future valuation risks.

Insider buying signals Scholar Rock’s R&D president buying shares just before Q4 earnings, hinting at confidence in its SMA therapy pipeline and potential upside for investors.

Insider sale by Scholar Rock’s CSO shows routine trading, not a crisis signal—evaluate the company’s pipeline vs. its negative valuation for smarter investing.

Insider buying by Scholar Rock’s CSO signals confidence in its biopharma pipeline – a green light for investors to hold or add, especially as trial data approaches.

Scholar Rock CFO’s tax‑cover sale shows disciplined equity plans and stable investor confidence, highlighting the firm’s commitment to long‑term growth.